Repare Therapeutics Inc. (NASDAQ:RPTX) Short Interest Update

Repare Therapeutics Inc. (NASDAQ:RPTX) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 194,336 shares, a decrease of 44.8% from the December 15th total of 352,361 shares. Based on an average daily trading volume, of 1,759,426 shares, the short-interest ratio is presently 0.1 days. Approximately 0.5% of the company’s stock are short sold. Approximately 0.5% of the company’s stock are short sold. Based on an average daily trading volume, of 1,759,426 shares, the short-interest ratio is presently 0.1 days.

Repare Therapeutics Stock Down 0.0%

NASDAQ RPTX opened at $2.60 on Thursday. Repare Therapeutics has a twelve month low of $0.89 and a twelve month high of $2.66. The stock has a market cap of $112.04 million, a P/E ratio of -1.54 and a beta of 0.97. The company’s 50-day simple moving average is $2.23 and its 200 day simple moving average is $1.86.

Repare Therapeutics (NASDAQ:RPTX) last issued its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.50 million. Research analysts anticipate that Repare Therapeutics will post -2.04 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on RPTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Monday, December 22nd. TD Cowen downgraded shares of Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 17th. Cowen downgraded shares of Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. Wall Street Zen upgraded shares of Repare Therapeutics to a “hold” rating in a research note on Saturday, November 15th. Finally, HC Wainwright decreased their price target on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday, October 27th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Trading of Repare Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Quinn Opportunity Partners LLC bought a new stake in shares of Repare Therapeutics during the 2nd quarter worth about $56,000. Lantern Wealth Advisors LLC acquired a new stake in Repare Therapeutics in the 3rd quarter worth about $35,000. Squarepoint Ops LLC acquired a new stake in Repare Therapeutics during the third quarter worth approximately $115,000. Rangeley Capital LLC acquired a new position in Repare Therapeutics in the second quarter valued at about $494,000. Finally, Militia Capital Partners LP acquired a new stake in shares of Repare Therapeutics during the 2nd quarter worth approximately $166,000. 85.09% of the stock is owned by institutional investors and hedge funds.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.